Tag Archives: biomarker

December, 2018

13 December
Roche to Develop Companion Diagnostic Test to Identify Patients Eligible for Anti-PD-1 Therapy Based on Biomarker Expression

TUCSON, Ariz., Dec. 11, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it entered into a collaboration with Merck (known as MSD outside the United States and Canada) to develop a companion diagnostic test to identify patients eligible for anti-PD-1 therapy based on the status of …
Share

27 June
Catabasis Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in DMD

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected by Duchenne muscular dystrophy (DMD). NF-kB is a fundamental driver of disease progression in DMD. These results add …
Share
6 June
Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose Hepatocellular Carcinoma

WASHINGTON, June 5, 2018 /PRNewswire/ — Researchers at Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic announced significant progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect hepatocellular carcinoma (HCC), the most common cancer that originates in the liver.1 The researchers detailed their findings during …
Share

18 January
OncoSec Provides Encouraging Clinical Observations Related to Triple Negative Breast Cancer Study

SAN DIEGO, Jan. 18, 2018 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced preliminary clinical observations related to its pilot biomarker OMS-I140 clinical trial of ImmunoPulse® IL-12 in patients with metastatic Triple Negative Breast Cancer (TNBC). The study is …
Share

3 November
New Interim Data Shows Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Alexion’s Kanuma

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that new interim data show that 80% of infants (8 out of 10) with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma® (sebelipase alfa) survived beyond 1 year of age.1 Patients also benefited from improvements in a number of …
Share

17 April
Bristol-Myers Squibb and Nordic Bioscience Collaborate for Fibrosis Biomarker Technology

NEW YORK & HERLEV, Denmark–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience …
Share

1 February
Catabasis’ Investigational Duchenne Muscular Dystrophy Drug Fails Mid-Stage Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 31, 2017– Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced top-line safety and efficacy results for Part B of the MoveDMD® trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD). The objective of Part B of the MoveDMD trial was to evaluate …
Share

7 December
Researchers Find New Biomarker for Brain Cancer Prognosis

DALLAS – Dec. 6, 2016 – Researchers at UT Southwestern Medical Center have found a new biomarker for glioma, a common type of brain cancer, that can help doctors determine how aggressive a cancer is and that could eventually help determine the best course of treatment. Researchers from the Harold …
Share

8 March
Definiens Launches Immunoprofiling Panel to Rapidly Screen Tissue Samples for Immune Responses

MUNICH–(BUSINESS WIRE)–Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of a new service, the Immunoprofiling Panel, to enable pharmaceutical companies, companion diagnostic developers and academic research centers working in immuno-oncology to quickly screen their target biomarkers and measure immune response. “Definiens leads …
Share

10 February
$1 Million Investment to Launch Grand Challenge to Develop a TDP43 Biomarker for ALS

WASHINGTON, Feb. 10, 2016 /PRNewswire-USNewswire/ — The ALS Association, in partnership with ALS Finding a Cure, is pleased to announce the Grand Challenge to generate a biomarker to track TDP43 aggregation. The successful team(s) with the most developed plan will receive up to a $1 million investment. ALS is a progressive …
Share